Dolutegravir/lamivudine/abacavir — Competitive Intelligence Brief

Dolutegravir/lamivudine/abacavir (Dolutegravir/lamivudine/abacavir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination (INSTI + NRTI backbone). Area: Infectious Disease / Virology.

phase 3 Antiretroviral combination (INSTI + NRTI backbone) HIV integrase, HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Dolutegravir/lamivudine/abacavir (Dolutegravir/lamivudine/abacavir) — Azienda Ospedaliera Universitaria Senese. This combination of three antiretroviral drugs inhibits HIV replication by blocking integrase and reverse transcriptase enzymes while providing nucleoside backbone coverage.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dolutegravir/lamivudine/abacavir TARGET	Dolutegravir/lamivudine/abacavir	Azienda Ospedaliera Universitaria Senese	phase 3	Antiretroviral combination (INSTI + NRTI backbone)	HIV integrase, HIV reverse transcriptase
BIC/FTC/TAF	BIC/FTC/TAF	Prism Health North Texas	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Bictegravir, emtricitabine, and tenofovir alafenamide	Bictegravir, emtricitabine, and tenofovir alafenamide	CAN Community Health	marketed	Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill	Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill	Charlotte-Paige Rolle, MD	marketed	Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Switch to B/F/TAF	Switch to B/F/TAF	University of Nairobi	marketed	Antiretroviral combination (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
ELV/COBI/FTC/TAF	ELV/COBI/FTC/TAF	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination therapy (integrase inhibitor + NRTI + NtRTI + pharmacokinetic booster)	HIV integrase, HIV reverse transcriptase
Regimen：BIC+FTC+TAF	Regimen：BIC+FTC+TAF	National Center for AIDS/STD Control and Prevention, China CDC	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination (INSTI + NRTI backbone) class)

1. Azienda Ospedaliera Universitaria Senese · 1 drug in this class